BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-519 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-519\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07607964-5456@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:ABBV-519: Phase 1 readout est. (NCT07607964)
DESCRIPTION:ABBV-519\, phase 1\, Systemic Lupus Erythematosus.\nStudy: A St
 udy to Assess Adverse Events\, How the Drug Moves Through the Body and Eff
 ectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-51
 9 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumat
 oid Arthritis (RA)\nEstimated primary completion: January 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/abbv-519#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07607964
URL:https://assetmemo.bio/drug/abbv-519#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
